| Old Articles: <Older 6751-6760 Newer> |
|---|
 |
The Motley Fool
October 7, 2010
Anders Bylund |
Orexigen Shares Popped: What You Need to Know Short interest in Orexigen has been high recently, and the stock is roaring back from a deep summer trough -- this could be a classic short squeeze.   |
The Motley Fool
October 7, 2010
Anders Bylund |
Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson. |
The Motley Fool
October 7, 2010
Brian D. Pacampara |
Delcath Shares Popped: What You Need to Know Is this meaningful? Or just another movement? |
The Motley Fool
October 7, 2010
Brian Orelli |
Asset Sold, Questions Begin Why did InterMune sells its stake in danoprevir? |
The Motley Fool
October 7, 2010 |
DRIP Portfolio Candidate: Becton, Dickinson Profit from your fear of needles by adding this stock to your DRIP portfolio. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns. |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
| <Older 6751-6760 Newer> Return to current articles. |
